top of page

Browse by category

Search

First patient in GLORY-2 study for mazdutide 9mg in Chinese adults with obesity

First patient in GLORY-2 study for mazdutide 9mg in Chinese adults with obesity

First patient in GLORY-2 study for mazdutide 9mg in Chinese adults with obesity

The first participant has been successfully dosed in Innovent Biologics’ Phase 3 clinical trial (GLORY-2) of higher dose 9mg mazdutide, a...

Mazdutide 9mg results in mean percent change in body weight of 15.4% at 24 weeks

Mazdutide 9mg results in mean percent change in body weight of 15.4% at 24 weeks

Mazdutide 9mg results in mean percent change in body weight of 15.4% at 24 weeks

Innovent Biologics has revealed its phase 2 clinical study of higher dose (9mg) mazdutide in Chinese adults with obesity achieved the...

Mazdutide anti-obesity drug achieves 11.7% body weight loss at 12-weeks

Mazdutide anti-obesity drug achieves 11.7% body weight loss at 12-weeks

Mazdutide anti-obesity drug achieves 11.7% body weight loss at 12-weeks

Innovent Biologics has announced that the results of a phase 1b study of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and...

Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesity

Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesity

Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesity

Innovent Biologics has announced that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical...

Metabolic bariatric surgery associated with an improvement in psoriasis outcomes

6 days ago

Postoperative complications of medical tourism may cost NHS up to £20,000 per patient

6 days ago

First patients randomised in KaiNETIC Global Phase 3 Clinical Program of ribupatide

7 days ago

Back to Top

bottom of page